13G Filing: Matrix Capital Management and Trillium Therapeutics Inc (TRIL)

Page 4 of 8 – SEC Filing

Item 1(a). NAME OF ISSUER.
The name of the issuer is Trillium Therapeutics Inc. (the “Company“).
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
The Company’s principal executive offices are located at 2488 Dunwin Drive, Mississauga, Ontario L5L 1J9, Canada.
Item 2(a). NAME OF PERSON FILING:
This statement is filed by:
(i)

Matrix Capital Management Company LP (the “Investment Manager“),
a Delaware limited partnership, and the investment adviser to Matrix Capital Management Master Fund, LP (the “Matrix Fund“),
with respect to the Common Shares (as defined in Item 2(d) below) directly held by the Matrix Fund; and

(ii) Mr. David E. Goel (the “Mr. Goel“), the Managing General Partner of the Investment Manager, with respect to the Common Shares directly held by the Matrix Fund.
The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Shares reported herein.
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
The address of the business office of each of the Reporting Persons is Bay Colony Corporate Center, 1000 Winter Street, Suite 4500, Waltham, MA 02451.
Item 2(c). CITIZENSHIP:
The Investment Manager is a Delaware limited partnership.  Mr. Goel is a citizen of the United States.
Item 2(d). TITLE OF CLASS OF SECURITIES:
Common Shares, no par value (the “Common Shares“).

Follow Trillium Therapeutics Inc. (NASDAQ:TRIL)